CD274 and hepatocellular carcinoma: Preliminary results from early-phase clinical trials in HCC indicated a superior treatment response when anti-PD-1 or anti-PD-L1 agents were combined with tyrosine kinase inhibitors (TKIs), including sorafenib, lenvatinib, regorafenib, and cabozantinib (3, 4).